ATIP - ATI Physical Therapy, Inc.
NYSE
->
Healthcare
->
Medical Care Facilities
Bolingbrook,
United States
Type: Equity
ATIP price evolution
ATIP
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 1 May 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $36.8 | $19.7 | $63.08 | |
| Short term investments | ||||
| Net receivables | $112.49 | $85 | $80.8 | $82.21 |
| Inventory | ||||
| Total current assets | $168.64 | $123.5 | $139 | $166.85 |
| Long term investments | ||||
| Property, plant & equipment | $294.85 | $317.5 | $333.6 | $344.23 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1003.28 | $978.5 | $1010.3 | $1045.76 |
| Current liabilities | ||||
| Accounts payable | $14.7 | $11.5 | $12.5 | $10.24 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $156.45 | $119.4 | $126.5 | $111.22 |
| Long term debt | $513.05 | $512.8 | $512 | $534.14 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $883.89 | $945.4 | $874.4 | $889.79 |
| Shareholders' equity | ||||
| Retained earnings | -$1409.31 | -$1403.7 | -$1388.5 | -$1365.78 |
| Other shareholder equity | $0.41 | -$89.2 | $0.6 | $1.44 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $36.8 | $83.14 | $48.62 | $1.31 |
| Short term investments | ||||
| Net receivables | $112.49 | $80.67 | $82.45 | $90.71 |
| Inventory | ||||
| Total current assets | $168.64 | $194.13 | $143.58 | $1.66 |
| Long term investments | ||||
| Property, plant & equipment | $294.85 | $349.78 | $396.38 | $395.4 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $345.02 | |||
| Total investments | ||||
| Total assets | $1003.28 | $1078.98 | $1562.69 | $346.68 |
| Current liabilities | ||||
| Accounts payable | $14.7 | $12.56 | $15.15 | $1.57 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $156.45 | $116.52 | $137.33 | $1.69 |
| Long term debt | $513.05 | $531.6 | $543.8 | $1154.75 |
| Total noncurrent liabilities | $339.99 | |||
| Total debt | ||||
| Total liabilities | $883.89 | $894.69 | $1058.28 | $341.68 |
| Shareholders' equity | ||||
| Retained earnings | -$1409.31 | -$1339.51 | -$847.13 | -$13.61 |
| Other shareholder equity | $0.41 | $4.9 | $0.03 | -$0 |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $156.79 | $163.29 | ||
| Cost of revenue | ||||
| Gross Profit | $15.07 | $23.28 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $28.06 | $35.31 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$7.22 | -$13.03 | ||
| Interest expense | -$11.78 | -$11.38 | ||
| Net income | ||||
| Net income | -$116.32 | -$135.55 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1.61 | |||
| Operating income | -$1.61 | |||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$13.61 | |||
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$21.86 | -$17.62 | -$8.66 | -$39.89 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $80.89 | $81.42 | $81.57 | -$11.52 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$0.05 | $31.06 | $46.18 | -$93.51 |
| (in millions $) | 31 Jan 2022 | 30 Jan 2021 | ||
|---|---|---|---|---|
| Net income | -$13.61 | |||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$0.56 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$39.89 | -$345 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$11.52 | $346.87 | ||
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$93.51 | $1.31 | ||
News
Fundamentals
| Market cap | $16.40M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 4.00M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 9.20 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.08 |
| Quick ratio | N/A |